These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 9129152

  • 21. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 22. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.
    Klampfer L, Huang J, Shirasawa S, Sasazuki T, Augenlicht L.
    Cancer Res; 2007 Sep 15; 67(18):8477-85. PubMed ID: 17875686
    [Abstract] [Full Text] [Related]

  • 23. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
    Jiang K, Delarue FL, Sebti SM.
    Oncogene; 2004 Feb 05; 23(5):1136-45. PubMed ID: 14647415
    [Abstract] [Full Text] [Related]

  • 24. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line.
    Fokstuen T, Rabo YB, Zhou JN, Karlson J, Platz A, Shoshan MC, Hansson J, Linder S.
    Anticancer Res; 1997 Feb 05; 17(4A):2347-52. PubMed ID: 9252645
    [Abstract] [Full Text] [Related]

  • 25. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
    Kukushkin AN, Abramova MV, Svetlikova SB, Darieva ZA, Pospelova TV, Pospelov VA.
    Oncogene; 2002 Jan 24; 21(5):719-30. PubMed ID: 11850800
    [Abstract] [Full Text] [Related]

  • 26. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
    Cesario A, Catassi A, Festi L, Imperatori A, Pericelli A, Galetta D, Margaritora S, Porziella V, Cardaci V, Granone P, Dominioni L, Russo P.
    Clin Cancer Res; 2005 Mar 01; 11(5):2026-37. PubMed ID: 15756029
    [Abstract] [Full Text] [Related]

  • 27. Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade.
    Oldham SM, Cox AD, Reynolds ER, Sizemore NS, Coffey RJ, Der CJ.
    Oncogene; 1998 May 01; 16(20):2565-73. PubMed ID: 9632133
    [Abstract] [Full Text] [Related]

  • 28. Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray.
    Tsunoda T, Nakamura T, Ishimoto K, Yamaue H, Tanimura H, Saijo N, Nishio K.
    Anticancer Res; 2001 May 01; 21(1A):137-43. PubMed ID: 11299727
    [Abstract] [Full Text] [Related]

  • 29. Farnesyl transferase inhibitors: current developments and future perspectives.
    Eskens FA, Stoter G, Verweij J.
    Cancer Treat Rev; 2000 Oct 01; 26(5):319-32. PubMed ID: 11006134
    [Abstract] [Full Text] [Related]

  • 30. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 01; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 31. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F, Park M, Goltzman D, Rabbani SA.
    Cancer Res; 1997 Oct 15; 57(20):4517-22. PubMed ID: 9377563
    [Abstract] [Full Text] [Related]

  • 32. Expression of CXC chemokine IP-10/Mob-1 by primary hepatocytes following heat shock.
    Hassanshahi G, Patel SS, Jafarzadeh AA, Dickson AJ.
    Saudi Med J; 2007 Apr 15; 28(4):514-8. PubMed ID: 17457469
    [Abstract] [Full Text] [Related]

  • 33. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ, Guitton JD, Baudoin B, Lelièvre Y, Duchesne M, Parker F, Fromage N, Commerçon A.
    J Med Chem; 1997 Jun 06; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract] [Full Text] [Related]

  • 34. [Inhibitors of isoprenylation of ras p21].
    Yoshimatsu K.
    Gan To Kagaku Ryoho; 1997 Sep 06; 24(11):1495-502. PubMed ID: 9309147
    [Abstract] [Full Text] [Related]

  • 35. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J, Schweizer P, Girgert R.
    Anticancer Res; 2002 Sep 06; 22(6C):4205-9. PubMed ID: 12553057
    [Abstract] [Full Text] [Related]

  • 36. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R, Kloog Y.
    Drug Resist Updat; 2005 Dec 06; 8(6):369-80. PubMed ID: 16356760
    [Abstract] [Full Text] [Related]

  • 37. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
    Zongaro S, de Stanchina E, Colombo T, D'Incalci M, Giulotto E, Mondello C.
    Cancer Res; 2005 Dec 15; 65(24):11411-8. PubMed ID: 16357149
    [Abstract] [Full Text] [Related]

  • 38. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 39. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
    Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB, Oliff A, Kohl NE.
    Mol Cell Biol; 1994 Jun 05; 14(6):4193-202. PubMed ID: 8196657
    [Abstract] [Full Text] [Related]

  • 40. Novel anticancer agents move closer to reality.
    Travis J.
    Science; 1993 Jun 25; 260(5116):1877-8. PubMed ID: 8316828
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.